Clinical Cancer Research, Vol 4, Issue 1 235-240, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1

H Aida, K Takakuwa, H Nagata, I Tsuneki, M Takano, S Tsuji, T Takahashi, T Sonoda, M Hatae, K Takahashi, K Hasegawa, H Mizunuma, N Toyoda, H Kamata, Y Torii, N Saito, K Tanaka, M Yakushiji, T Araki and K Tanaka
Department of Obstetrics and Gynecology, Niigata University School of Medicine, Japan.

We analyzed the clinical features of 25 ovarian cancer patients who were associated with germ-line mutations of BRCA1 from four site-specific ovarian cancer families and seven breast-ovarian cancer families in Japan. The average age at diagnosis was 51.1 years (range, 38-77 years). Histological examination revealed 24 serous cyst adenocarcinomas in 25 patients. In 23 patients with clear clinical records, 3 patients had stage I disease, 17 had stage III disease, and 3 had stage IV disease. Thirteen patients with stage III disease who were treated with cisplatin-containing chemotherapy following tumor reduction surgery showed more favorable outcomes in both the survival rate and disease-free intervals, compared with age- and treatment course-matched controls (5-year survival rate, 0.786 versus 0.303; median disease-free interval, 91.43 versus 40.92 months; P < 0.05 for both, by logarithmic rank test). Our statistical model for the inheritance of susceptibility to ovarian cancer was derived from the analysis of 26 patients and 19 healthy carriers of 12 families. The expected lifetime risk of ovarian cancer is about 80% for women with mutations of BRCA1. These results suggest that the clinical outcome of ovarian cancer with germ-line mutations of BRCA1 appears to be more favorable than that with sporadic cases and that the disease penetrance among pedigrees with germ-line mutations of the BRCA1 gene is substantially high.

This article has been cited by other articles:

				A. W. Kurian, G. D. Gong, N. M. Chun, M. A. Mills, A. D. Staton, K. E. Kingham, B. B. Crawford, R. Lee, S. Chan, S. S. Donlon, et al. Performance of BRCA1/2 Mutation Prediction Models in Asian Americans J. Clin. Oncol., October 10, 2008; 26(29): 4752 - 4758. [Abstract] [Full Text] [PDF]

				A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer J. Clin. Oncol., January 1, 2008; 26(1): 20 - 25. [Abstract] [Full Text] [PDF]

				I. Cass, C. Holschneider, N. Datta, D. Barbuto, A. E. Walts, and B. Y. Karlan BRCA-Mutation-Associated Fallopian Tube Carcinoma: A Distinct Clinical Phenotype? Obstet. Gynecol., December 1, 2005; 106(6): 1327 - 1334. [Abstract] [Full Text] [PDF]

				H. M. Sowter and A. Ashworth BRCA1 and BRCA2 as ovarian cancer susceptibility genes Carcinogenesis, October 1, 2005; 26(10): 1651 - 1656. [Abstract] [Full Text] [PDF]

				S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al. Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481. [Abstract] [Full Text] [PDF]

				R. E. Buller, M. S. Shahin, J. P. Geisler, M. Zogg, B. R. De Young, and C. S. Davis Failure of BRCA1 Dysfunction to Alter Ovarian Cancer Survival Clin. Cancer Res., May 1, 2002; 8(5): 1196 - 1202. [Abstract] [Full Text] [PDF]

				Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller, G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, et al. Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors J. Clin. Oncol., January 15, 2002; 20(2): 463 - 466. [Abstract] [Full Text] [PDF]

				M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al. Mutational Analysis of BRCA1 and BRCA2 and Clinicopathologic Analysis of Ovarian Cancer in 82 Ovarian Cancer Families: Two Common Founder Mutations of BRCA1 in Japanese Population Clin. Cancer Res., October 1, 2001; 7(10): 3144 - 3150. [Abstract] [Full Text] [PDF]

				M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, M. Hatae, I. Kobayashi, T. Fujii, I. Nagata, K. Ushijima, et al. Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25 Hum. Mol. Genet., June 1, 2001; 10(13): 1421 - 1429. [Abstract] [Full Text] [PDF]

				V. McGuire, A. S. Whittemore, R. Norris, and I. Oakley-Girvan Survival in Epithelial Ovarian Cancer Patients with Prior Breast Cancer Am. J. Epidemiol., September 15, 2000; 152(6): 528 - 532. [Abstract] [Full Text] [PDF]

				J. Boyd, Y. Sonoda, M. G. Federici, F. Bogomolniy, E. Rhei, D. L. Maresco, P. E. Saigo, L. A. Almadrones, R. R. Barakat, C. L. Brown, et al. Clinicopathologic Features of BRCA-Linked and Sporadic Ovarian Cancer JAMA, May 3, 2000; 283(17): 2260 - 2265. [Abstract] [Full Text] [PDF]

				L. Kasprzak, W. D Foulkes, and A. N Shelling Fortnightly review: Hereditary ovarian carcinoma BMJ, March 20, 1999; 318(7186): 786 - 789. [Full Text]